Core Viewpoint - The company is developing a multi-target peptide drug, RAY0221, which is aimed at treating diabetes, obesity, and non-alcoholic fatty liver disease, currently in the preclinical research phase [1] Group 1 - The drug RAY0221 has GLP-1/GIP/GCG three-target activity [1] - The project is progressing as planned in its development [1] - The company is committed to advancing the project in an orderly manner [1]